HIV Protease: Historical Perspective and Current Research [PDF]
Viruses, 2021 The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by ...
Irene T. Weber +2 more
doaj +4 more sources
Susceptibility of HPV-18 Cancer Cells to HIV Protease Inhibitors [PDF]
VirusesCervical cancer cases continue to rise despite all the advanced screening and preventative measures put in place, which include human papillomavirus (HPV) vaccination.
Lilian Makgoo +2 more
doaj +2 more sources
Molecular Mechanisms of HIV Protease Inhibitors Against HPV-Associated Cervical Cancer: Restoration of TP53 Tumour Suppressor Activities [PDF]
Frontiers in Molecular Biosciences, 2022 Cervical cancer is a Human Papilloma virus-related disease, which is on the rise in a number of countries, globally. Two essential oncogenes, E6 and E7, drive cell transformation and cancer development.
Lilian Makgoo +2 more
doaj +2 more sources
HIV protease inhibitors restore amphotericin B activity against Candida. [PDF]
PLoS ONECandida auris is an invasive fungal pathogen, representing a global public health threat. It is characterized by high mortality rates among infected individuals, significant antifungal resistance, and a remarkable ability to persist in healthcare ...
Yehia Elgammal +2 more
doaj +2 more sources
HIV protease cleaves the antiviral m6A reader protein YTHDF3 in the viral particle. [PDF]
PLoS Pathogens, 2020 N6-methyladenosine (m6A) is the most abundant HIV RNA modification but the interplay between the m6A reader protein YTHDF3 and HIV replication is not well understood.
Denise Jurczyszak +9 more
doaj +2 more sources
Molecular Basis for Drug Resistance in HIV-1 Protease
Viruses, 2010 HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of structure-based drug design, thus the atomic details of how the ...
Celia A. Schiffer +12 more
doaj +3 more sources
Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells. [PDF]
PLoS Pathogens, 2010 In medicine, understanding the pathophysiologic basis of exceptional circumstances has led to an enhanced understanding of biology. We have studied the circumstance of HIV-infected patients in whom antiretroviral therapy results in immunologic benefit ...
Sekar Natesampillai +6 more
doaj +1 more source
Infected cell killing by HIV-1 protease promotes NF-kappaB dependent HIV-1 replication. [PDF]
PLoS ONE, 2008 Acute HIV-1 infection of CD4 T cells often results in apoptotic death of infected cells, yet it is unclear what evolutionary advantage this offers to HIV-1.
Gary D Bren +6 more
doaj +1 more source
HIV protease inhibitors and obesity [PDF]
Current Opinion in Endocrinology, Diabetes and Obesity, 2010 To review the current scientific literature and recent clinical trials on HIV protease inhibitors and their potential role in the pathogenesis of lipodystrophy and metabolic disorders.HIV protease inhibitor treatment may affect the normal stimulatory effect of insulin on glucose and fat storage.
Erdembileg, Anuurad +2 more
openaire +2 more sources
Predicting HIV-1 Protease Cleavage Sites With Positive-Unlabeled Learning
Frontiers in Genetics, 2021 Understanding the substrate specificity of HIV-1 protease plays an essential role in the prevention of HIV infection. A variety of computational models have thus been developed to predict substrate sites that are cleaved by HIV-1 protease, but most of ...
Zhenfeng Li +3 more
doaj +1 more source